Communiqués Nuvectra Corporation

Actions

NVTRQ

US67075N1081

Equipement, fournitures et distribution médicale

Temps Différé OTC Markets Autres places de cotation			Varia. 5j.	Varia. 1 janv.
- ^USD	-.--%		+16,67%	-85,26%

31/07/19	Transcript : Nuvectra Corporation, Q2 2019 Earnings Call, Jul 31, 2019
31/07/19	Nuvectra Corporation révise ses prévisions de revenus pour 2019	CI

Communiqués

20/04/20	NUVECTRA CORP : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
25/03/20	NUVECTRA CORP : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
16/03/20	NUVECTRA CORP : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
13/02/20	NUVECTRA CORP : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
31/01/20	NUVECTRA CORP : Other Events (form 8-K)	AQ
15/01/20	NUVECTRA CORP : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
31/12/19	NUVECTRA CORP : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
12/11/19	Nuvectra® Continuing to Support Current Patients with the Algovita® Implant as Company Voluntarily Files for Chapter 11	GL
18/10/19	Nuvectra Submits Chemical Composition and Biocompatibility Data to FDA for Virtis™	GL
20/09/19	Nuvectra® Appoints Jennifer Kosharek as Chief Financial Officer	GL
26/08/19	Nuvectra® Exploring Strategic Options to Enhance Shareholder Value	GL
31/07/19	Nuvectra® Reports Second Quarter 2019 Financial Results	GL
17/07/19	Nuvectra to Report Second Quarter 2019 Financial Results on July 31, 2019	GL
12/06/19	Nuvectra® to Participate in Two Upcoming Investor Conferences	GL
11/06/19	Nuvectra Files Regulatory Submission with FDA for Algovita® Full-Body MR-Conditional Approval	GL
30/05/19	Nuvectra Highlights Positive Preliminary Algovita® Clinical Data at the INS 14th Annual World Congress	GL
22/04/19	Nuvectra to Report First Quarter 2019 Financial Results on May 1, 2019	GL
28/02/19	Nuvectra® Reports Fourth Quarter and Full Year 2018 Financial Results	GL
26/02/19	Nuvectra® to Present at 39th Annual Cowen Healthcare Conference	GL
19/02/19	Nuvectra to Report Fourth Quarter and Full Year 2018 Financial Results on February 28, 2019	GL
31/01/19	Nuvectra® Appoints Dr. Fred B. Parks as Chief Executive Officer	GL
07/01/19	Nuvectra® Announces Preliminary Unaudited Fourth Quarter and Full Year 2018 Revenue	GL
02/01/19	Nuvectra Announces Divesture of NeuroNexus Subsidiary	GL
12/12/18	Nuvectra Receives Full-Body MR-Conditional CE Mark Approval for Algovita®	GL
06/12/18	Nuvectra Completes 3,000 U.S. Algovita® SCS Implantations	GL